Andersson, Y.; Fleten, K.G.; Abrahamsen, T.W.; Reed, W.; Davidson, B.; Flatmark, K.
Anti-Angiogenic Treatment in Pseudomyxoma Peritonei—Still a Strong Preclinical Rationale. Cancers 2021, 13, 2819.
https://doi.org/10.3390/cancers13112819
AMA Style
Andersson Y, Fleten KG, Abrahamsen TW, Reed W, Davidson B, Flatmark K.
Anti-Angiogenic Treatment in Pseudomyxoma Peritonei—Still a Strong Preclinical Rationale. Cancers. 2021; 13(11):2819.
https://doi.org/10.3390/cancers13112819
Chicago/Turabian Style
Andersson, Yvonne, Karianne G. Fleten, Torveig W. Abrahamsen, Wenche Reed, Ben Davidson, and Kjersti Flatmark.
2021. "Anti-Angiogenic Treatment in Pseudomyxoma Peritonei—Still a Strong Preclinical Rationale" Cancers 13, no. 11: 2819.
https://doi.org/10.3390/cancers13112819
APA Style
Andersson, Y., Fleten, K. G., Abrahamsen, T. W., Reed, W., Davidson, B., & Flatmark, K.
(2021). Anti-Angiogenic Treatment in Pseudomyxoma Peritonei—Still a Strong Preclinical Rationale. Cancers, 13(11), 2819.
https://doi.org/10.3390/cancers13112819